Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -39.2%
- Operating Margin Trend +2487.85 pp/yr
ARQT
Arcutis Biotherapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -122.2%
- 5yr Share-Count CAGR 29.0%
Growth Quality
Weight: 35%
C+
60
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -2024.4%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
B
70
- Net Debt / EBITDA -120.63x
- Interest Coverage (EBIT/Int) -0.24x
- Altman Z-Score 7.82
Stability
Weight: 5%
B
70
- Negative-Revenue Years (5) 0/5
- Piotroski F-Score 4
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 new buy; 1 added; 1 trimmed.
- Holders
- 3 +1
- Avg Δ position
- +9.8%
- New buys
- 1
- Full exits
- 0
- Greenblatt new
- Cooperman increased +58%
- Wood decreased -39%